Transcatheter Arterial Chemoembolization Is a Feasible Palliative Locoregional Therapy for Breast Cancer Liver Metastases

Table 2

Details of TACE treatments and tumor response of breast cancer patients with hepatic metastases.

Patient	Chemothe-rapeutic Agent	Dose of chemotherapy used in each cycle (mg/m^2)	Number of TACE cycles	Interval between first TACE and death/last F/U (in  month)	Interval between diagnosis of liver metastasis and death/last F/U (in month)	Radiological response after third TACE	Radiological response after last TACE	Tumor marker response	New extrahepatic metastasis during TACE	Morbidity of TACE
1	adriamycin	80	3	6	12	progression	progression	CA125-increase	new left axillary LN	neutropenia
2	cisplatin/ Gemcitabine	125/1250	3	7	64	progression	progression	CA125-increase CA153-increase	new pulmonary metastasis	none
3	oxaliplatin	85	1	1	1	N/A	progression	CA153-increase CA125-decrease	none	nausea & vomiting
4	cisplatin	165	5	12	19	progression	progression	CA125-increase CA153-increase	new bony metastasis	nausea & vomiting
5	adriamycin	40	5	16	42	stable disease	partial response	CEA-decrease CA153-decrease	new bony metatasis	nausea, neutropenia
6	adriamycin	50∼60	5	16	65	progression	progression	CA153-decrease	none	nausea, abdo pain neutropenia, anemia
7	cisplatin gemcitabine	150/1500	3	24	24	partial response	partial response	CA153-decrease	none	nausea
8	adriamycin	50	3	8	28	progression	progression	CA153-increase	none	abdo pain
9	adriamycin	50	4	9	9	stable disease	stable disease	CA153-decrease	new bony metastasis	abdo pain
10	adriamycin	40	10	26	39	stable disease	stable disease	CA153-decrease	new bony metastasis	none